These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27817998)

  • 21. Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis.
    Wang TY; Honeycutt EF; Tapson VF; Moll S; Granger CB; Ohman EM
    Am J Med; 2012 Dec; 125(12):1214-21. PubMed ID: 22939359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
    Ozsu S; Korkmaz A; Bülbül Y; Oztuna F; Ozlü T
    Tuberk Toraks; 2011; 59(2):178-83. PubMed ID: 21740395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux.
    Maetzke J; Hinrichs R; Schneider LA; Scharffetter-Kochanek K
    Allergy; 2005 Mar; 60(3):413-5. PubMed ID: 15679737
    [No Abstract]   [Full Text] [Related]  

  • 25. Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?
    Badger NO
    J Pharm Pract; 2010 Jun; 23(3):235-8. PubMed ID: 21507819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
    Steinfeldt T; Rolfes C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients.
    Benken ST; Tillman N; Dajani S; Shah A; Thomas T
    J Cardiothorac Surg; 2014 Mar; 9():55. PubMed ID: 24656312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Outpatient use of heparin: data from the Midi-Pyrenes Health Fund].
    Berchery D; Roussel H; Bourrel R; Sciortino V
    Therapie; 2003; 58(5):431-7. PubMed ID: 14682192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.
    Willenborg KL
    Pharmacotherapy; 2014 Jun; 34(6):e55-9. PubMed ID: 24644124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Erythema after subcutaneous heparin treatment].
    Brouns AJ; Jie KS
    Ned Tijdschr Geneeskd; 2015; 159():A9304. PubMed ID: 26507065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HIT treatment in a cardiac surgery patient.
    Anna N; Boyan T; Kader MA; Catherine M; Matthias K
    Int J Cardiol; 2010 Oct; 144(3):405-7. PubMed ID: 19324432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
    Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
    Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin-induced thrombocytopenia in a hemodialysis patient treated with fondaparinux: nephrologists between two fires.
    Solak Y; Demircioglu S; Polat I; Biyik Z; Gaipov A; Acar K; Turk S
    Hemodial Int; 2013 Apr; 17(2):320-3. PubMed ID: 22631215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
    Oliveira GB; Crespo EM; Becker RC; Honeycutt EF; Abrams CS; Anstrom KJ; Berger PB; Davidson-Ray LD; Eisenstein EL; Kleiman NS; Moliterno DJ; Moll S; Rice L; Rodgers JE; Steinhubl SR; Tapson VF; Ohman EM; Granger CB;
    Arch Intern Med; 2008 Jan; 168(1):94-102. PubMed ID: 18195201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Warkentin TE; Greinacher A
    Chest; 2004 Sep; 126(3 Suppl):311S-337S. PubMed ID: 15383477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.